Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Daily

Download Data

Edgewise Therapeutics Inc Price to Earnings Ratio (P/E) on June 03, 2024: -75.74

Edgewise Therapeutics Inc Price to Earnings Ratio (P/E) is -75.74 on June 03, 2024, a -866.64% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Edgewise Therapeutics Inc 52-week high Price to Earnings Ratio (P/E) is -0.03 on May 06, 2024, which is 99.96% above the current Price to Earnings Ratio (P/E).
Edgewise Therapeutics Inc 52-week low Price to Earnings Ratio (P/E) is -92.37 on May 07, 2024, which is -21.96% below the current Price to Earnings Ratio (P/E).
Edgewise Therapeutics Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -19.20.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends